Cuban Academy of Sciences develops vaccines for the treatment of non-small cell lung cancer- Vaxira and CIMAvax. This latest type of vaccine that can treat non-small cell lung cancer (NSCLC) has undergone phase 3 clinical validation and has a good effect on non-small cell lung cancer. It has now entered clinical applications in Cuba iyo Peru. Natiijooyinka ka soo baxay cilmi-baaristaan xiisaha lihi waxay awood u siisay Madaxweynihii hore ee Mareykanka Barack Obama in laga qaado xayiraada ganacsiga ee saaran 55 sano kadib booqashada Cuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
Waa maxay CIMAvax?
CIMAvax-EGF is a kansarka sanbabada treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced kansarka sanbabada ee aan yareyn (NSCLC).
Sidee ayuu u shaqeeyaa CIMAvax?
Waxaa soo saaray cilmi-baarayaasha Xarunta Immunology Molecular (CIM) ee Havana, Cuba, CIMAvax-EGF waxay xannibaysaa nooc ka mid ah borotiinka - factor koritaanka epidermal (EGF) - in unugyada kansarku ay u baahan yihiin inay koraan. Si toos ah uma disho unugyada, unugyada kansarka ama haddii kale, laakiin waxay "gaajoonaysaa" iyaga oo ka hortagaya EGF inay ku xirto qaboojiyaha saxda ah (EGFR) ee unugyada. Isku xirkan ayaa looga baahan yahay unuggu inuu koro oo uu bato. La'aanteed, unugga kansarku ma tarmo, wuuna dhintaa. CIMAvax waxay xannibtaa EGF iyadoo wax ka beddelaysa jawaabta difaaca bukaanka.
“Protein side” ee ku jira CIMAvax wuxuu kiciyaa nidaamka difaaca jirka si uu u soo saaro unugyada kahortaga borotiinka EGF si looga takhaluso. Tani waxay baabi'ineysaa wareejinta EGF ee dhiigga, taasoo ka reebaysa unugyada kansarka furahan muhiimka ah ee koritaanka iyo badbaadada.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged buro stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Waa maxay Vaxira?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Racotumomab waa anti-idiotypic monoclonal antibody taas oo bukaanada ku kicisa jawaab celin xoog leh oo ka dhan ah gangliosides glycolylated gaar ah (NeuGcGM3) oo ku jira unugyada burooyinka. Vaxira® waxay kordhisaa badbaadada bukaanka NSCLC ee heerarka soo noqnoqda ama heerka sare (IIIB / IV) marka la barbar dhigo daryeelka ugu fiican ee taageerada. Vaxira® sifiican ayaa loo dulqaatay oo astaanteeda amaan waa mid la aqbali karo. Inta badan dhacdooyinka qallafsan ee caadiga ah waa kuwo ku-meel-gaadh ah (goobta maamulka), fudeyd iyo ku-meel-gaadh ah.
Xitaa bukaanada lagu tallaalay Vaxira® ka dib markii cudurkoodu sii xumaaday waxay muujiyeen horumarin guud ahaan badbaadada.
Dejinta: Weel kasta oo ka mid ah VAXIRA® wuxuu ka kooban yahay: mAb Racotumomab 1.00 mg, aluminium hydroxide [Al (OH) 3] 5.00 mg, tris (hydroxymethyl) aminomethane 12.14 mg, sodium chloride 3.40 mg, biyo lagu durayo qs 1.0 ml. Vaxira® waa wakiil difaaca jirka ka kooban oo ka kooban anti-idiotypic monoclonal antibody Racotumomab iyo aluminium hydroxide (AH), oo ah adeegsi aad loo isticmaalo. AH wuxuu kobciyaa soo saarista unugyada difaaca jirka, laakiin ma aha mid difaaca jirka ama hapten ah. Waxay u dhaqantaa sidii bakhaar goobta lagu duray oo antigen si tartiib ah looga sii daayo isla markaa, waxay kicisaa sameynta granulomas oo soo jiidata unugyada difaaca jirka sida unugyada plasma ee unugyada soo saara. AH waxay si toos ah u kicin kartaa monocytes si loo soo saaro cytokines proinflammatory oo firfircoon kara unugyada T, sidoo kale waxay kicin kartaa jawaabta unugga B.
Sidee looga iibsadaa CIMAvax iyo Vaxira gudaha Hindiya?
CIMAvax and Vaxira at present are not available in Hindiya. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
